| Primary |
| Mucopolysaccharidosis I |
64.3% |
| Product Used For Unknown Indication |
18.1% |
| Mucopolysaccharidosis |
11.4% |
| Premedication |
2.0% |
| Mucopolysaccharidosis Ih |
1.6% |
| Bone Marrow Transplant |
0.3% |
| Epilepsy |
0.3% |
| Mucopolysaccharidosis Ih/s |
0.3% |
| Pain |
0.3% |
| Spinal Cord Compression |
0.3% |
| Bone Marrow Conditioning Regimen |
0.2% |
| Cardiac Valve Disease |
0.2% |
| Neck Pain |
0.2% |
| Allogenic Bone Marrow Transplantation Therapy |
0.1% |
| Anticoagulant Therapy |
0.1% |
| Drug Therapy |
0.1% |
| Drug Use For Unknown Indication |
0.1% |
| Glycogen Storage Disease Type Ii |
0.1% |
| Immunosuppressant Drug Therapy |
0.1% |
| Infusion |
0.1% |
|
| Pneumonia |
12.8% |
| Death |
9.5% |
| Respiratory Failure |
9.5% |
| Vomiting |
9.5% |
| Urticaria |
5.9% |
| Respiratory Distress |
5.2% |
| Cardiac Failure |
4.6% |
| Weight Decreased |
4.3% |
| Pyrexia |
3.9% |
| Sepsis |
3.9% |
| Spinal Cord Compression |
3.9% |
| Mucopolysaccharidosis I |
3.3% |
| Stem Cell Transplant |
3.3% |
| Tachycardia |
3.3% |
| Upper Respiratory Tract Infection |
3.3% |
| Cardiopulmonary Failure |
3.0% |
| Dyspnoea |
3.0% |
| Bronchopneumonia |
2.6% |
| Infusion Related Reaction |
2.6% |
| Sleep Apnoea Syndrome |
2.6% |
|
| Secondary |
| Mucopolysaccharidosis I |
72.2% |
| Product Used For Unknown Indication |
8.7% |
| Stem Cell Transplant |
7.0% |
| Mucopolysaccharidosis |
3.5% |
| Mucopolysaccharidosis Ih |
3.5% |
| Premedication |
2.6% |
| Mucopolysaccharidosis Ih/s |
1.7% |
| Anticoagulant Therapy |
0.9% |
|
| Urinary Glycosaminoglycans Increased |
30.0% |
| Urticaria |
12.0% |
| Pneumonia |
6.0% |
| Wheezing |
6.0% |
| Multi-organ Failure |
4.0% |
| Oxygen Saturation Decreased |
4.0% |
| Respiratory Failure |
4.0% |
| Restlessness |
4.0% |
| Staphylococcal Sepsis |
4.0% |
| Sudden Death |
4.0% |
| Vomiting |
4.0% |
| Dyspnoea |
2.0% |
| Laryngeal Oedema |
2.0% |
| Pneumonia Viral |
2.0% |
| Pregnancy |
2.0% |
| Premature Labour |
2.0% |
| Pulmonary Hypertension |
2.0% |
| Pyrexia |
2.0% |
| Renal Impairment |
2.0% |
| Sepsis |
2.0% |
|
| Concomitant |
| Bone Marrow Transplant |
25.0% |
| Respiratory Disorder |
25.0% |
| Bone Marrow Conditioning Regimen |
12.5% |
| Growth Hormone Deficiency |
12.5% |
| Mucopolysaccharidosis I |
12.5% |
| Stem Cell Transplant |
12.5% |
|
| Erythema Multiforme |
40.0% |
| Lymphoproliferative Disorder |
20.0% |
| Multi-organ Failure |
20.0% |
| Osteochondrosis |
20.0% |
|
